Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR27 | Q9NS67 | 9/20 | 0.66 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.66 |
| ▸ | CCR9 | P51686 | 2/20 | 0.64 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.61 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.61 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.59 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.59 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110940 | 0.93 | SLC10A6 (0.68) | GPR27AVPR2CCR9SLC20A2SLC20A1 | |
| SCHEMBL6860504 | 0.91 | SLC10A6 (0.59) | GPR27AVPR2CCR9SLC20A2SLC20A1 | |
| SCHEMBL5120085 | 0.88 | SLC20A2 (0.63) | GPR27AVPR2CCR9SLC20A2SLC20A1 | |
| SCHEMBL5111449 | 0.87 | SLC10A2 (0.65) | GPR27AVPR2SLC20A2SLC20A1SLC10A2 | |
| SCHEMBL7213211 | 0.87 | GPR27 (0.67) | GPR27AVPR2CCR9SLC20A2SLC20A1 | |
| SCHEMBL5111523 | 0.87 | SLC10A6 (0.61) | GPR27AVPR2CCR9SLC20A2SLC20A1 | |
| SCHEMBL7213042 | 0.86 | LMNA (0.69) | GPR27AVPR2KCNA5 | |
| SCHEMBL5125757 | 0.85 | SLC10A6 (0.69) | GPR27AVPR2SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL10249221 | 0.85 | ACLY (0.67) | CCR9 | |
| SCHEMBL27857 | 0.84 | LMNA (0.77) | CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | GPR27 108/4885AVPR2 2573/4885CCR9 1/4885 |
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | GPR27 108/4885AVPR2 2573/4885CCR9 1/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | GPR27 108/4885AVPR2 2573/4885CCR9 1/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | GPR27 108/4885AVPR2 2573/4885CCR9 1/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | GPR27 108/4885AVPR2 2573/4885CCR9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.